Lamera

Olmesartan medoxomil and amlodipine, the active ingredient in Lamera, is an Angiotensin II receptor blocker (ARB) and calcium channel blocker presented as an oral tablet formulation for oral use. It is indicated for the management of hypertension in adult patients. GNH USA supplies Lamera as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamera combines an ARB and a calcium‑channel blocker to treat elevated blood pressure within the hypertension therapeutic area.

Hypertension: provides sustained blood‑pressure reduction in patients with essential hypertension, helping to lower the risk of cardiovascular complications.

Lamera may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness, especially after standing. - Flushing: transient warmth or redness of the skin.

Serious or Rare Side Effects: - Angio‑edema: rapid swelling of face, lips, or throat. - Severe hypotension: marked drop in blood pressure causing faintness. - Hepatic dysfunction: abnormal liver enzyme elevations. - Hyperkalemia: elevated potassium levels in blood. - Renal impairment: worsening kidney function in susceptible individuals.

Before initiating Lamera, consider patient‑specific factors and monitor relevant parameters. - Renal function: assess creatinine clearance and adjust therapy if needed. - Hepatic disease: use cautiously in patients with liver impairment. - Electrolytes: monitor potassium and sodium levels regularly. - Pregnancy and lactation: avoid use unless clearly indicated by a physician. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Lamera can interact with several drug classes; awareness of the interaction potential helps optimize therapy.

Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: may cause hyperkalemia. - Strong CYP3A4 inhibitors (e.g., clarithromycin): can increase amlodipine exposure.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may attenuate antihypertensive effect and affect renal function. - Lithium: concurrent use may raise lithium levels. - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): increased risk of hypotension and renal dysfunction.